Testing HS-10365 for advanced lung cancer with RET gene fusion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 clinical trial evaluates the safety and effectiveness of HS-10365, a selective RET inhibitor, in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. The study is open-label and single-arm, meaning all participants will receive the same treatment without a control group. Participants will take HS-10365 orally twice daily until disease progression or unacceptable side effects occur. The primary goal is to measure the objective response rate, while secondary objectives include assessing safety and pharmacokinetics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Men or women aged more than or equal to (≥) 18 years.
2. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC with RET fusion-positive, including recurrent or initial diagnosed Stage IIIB-IIIC/IV NSCLC that is not suitable for radical surgery.
3. A RET gene fusion is required by using tumor tissue for central testing.
4. At least one measurable lesion in accordance with RECIST 1.1
5. Eastern Cooperative Oncology Group (ECOG) performance status: 0\~1.
6. Estimated life expectancy \>12 weeks.
7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.
8. Females must have evidence of non-childbearing potential.
9. Signed and dated Informed Consent Form.

Exclusion Criteria:

1. Treatment with any of the following:

   Additional validated oncogenic drivers in NSCLC if known. Previous or current treatment with selective RET inhibitors or multi-kinase Inhibitor of RET.

   Prior systemic therapy for metastatic disease. Treatment (including chemotherapy or immunotherapy) in the adjuvant/neoadjuvant setting is permitted if it was completed at least 6 months prior to relapse.

   Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.

   Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
2. Inadequate bone marrow reserve or serious organ dysfunction.
3. Uncontrolled pleural effusion or ascites or pericardial effusion.
4. Known and untreated, or active central nervous system metastases.
5. Active autoimmune diseases or active infectious disease
6. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.
7. History of severe allergic reaction, hypersensitivity to any active or inactive ingredient of HS-10365 or to drugs with a similar chemical structure or class to HS-10365.
8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.
9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.
10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.
11. History of neuropathy or mental disorders, including epilepsy and dementia

Where it's running

• Shanghai Chest Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Shun Lu, MD — Shanghai Chest Hospital
• Study coordinator: Shun Lu, MD
• Email: shun_lu@hotmail.com
• Phone: 13601813062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• AI helps a multidisciplinary team decide NSCLC treatment

  This study tests whether a local AI decision-support model can match or influence treatment choices made by a traditional MDT for non-small cell lung cancer patients.

  Recruiting Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07626736

• Evaluating DZD6008 for advanced lung cancer with EGFR mutations

  This study is testing a new oral medication called DZD6008 to see if it can safely help people with advanced lung cancer who have specific EGFR mutations.

  Recruiting Phase 1 Dizal Pharmaceuticals · Beijing, Beijing Municipality · NCT06813365

• Evaluating the safety of a new treatment for certain cancer types

  This study is testing a new treatment for certain types of cancer to see if it's safe for adults with recurrent or metastatic tumors.

  Recruiting at 4 sites Phase 1 Orano Med LLC · Chicago, Illinois and 7 other locations · NCT05283330

• Supportive care model for patients with advanced lung cancer

  This study is testing a new supportive care program for people with advanced lung cancer to see if it helps them feel less stressed and more confident about managing their condition compared to standard care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT04900935

• Comparing treatment outcomes in lung cancer patients with different performance statuses

  This study is testing if immunotherapy treatments can help lung cancer patients with lower performance status feel better and live longer compared to those with better performance status.

  Recruiting at 2 sites Phase 2 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT04253964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.